.png)
Kin Therapeutics applies the most advanced biopharmaceutical strategies to treat connective tissue diseases
Connective tissue disorders include several genetic diseases impacting the extracellular matrix and bone. There are over 200 heritable disorders of connective tissue. One area of focus is the rare genetic disorder called Ehlers Danlos (classical and vascular types). People with Ehlers Danlos have mutations in Collagen that cause joint hypermobility, skin defects, vascular and soft tissue abnormalities and even early death. Other genetic diseases of connective tissue that we study include Marfan Syndrome and Osteogenesis Imperfecta. The extracellular matrix plays a vital role in many bone and connective tissues disorders, cardiovascular disease, and dermatological conditions. More common types of connective tissue disorders include rheumatoid arthritis, firbromyalgia, scleroderma, and lupus. Our research and drug development efforts aim to find solutions for these debilitating conditions.
.jpg)
Research
We are passionate about researching the cause and potential treatments of rare genetic diseases of connective tissues. Kin Therapuetics staff is skilled at the study of extracellular matrix components, and the cell biology relevant to connective tissue diseases. We are using advanced stem cell engineering techniques and cutting edge gene editing strategies to advance our pipeline.
Development
Gene and cell therapies are being developed at Kin Therapeutics. Kin Therapeutics has programs to study connective tissue diseases that include vascular and hypermobile Ehlers Danlos Syndrome, Marfan Syndrome, and Osteogenesis Imperfecta (caused by mutations in genes-Col3A1, Col5A1, FBN1, and Col1A1 respectively). We utilize advanced gene editing techniques and cell therapy to develop a therapeutic intervention. Cell Therapy uses cells removed from a patient, genetically altered, and then applied as a treatment to improve clinical outcomes. Drugs that can enhance normal extracellular matrix production and function are also being studied at Kin Therapeutics. Our therapies have implications beyond rare diseases of connective tissue and could be used to treat orthopedic, cardiovascular and dermatological disorders. With support of scientific and financial partners we intend to advance our therapeutics into the clinic.